Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to
inhibit blood coagulation at various stages, reducing clot development and ultimately …

Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

Options for anticoagulation have been expanding steadily over the past few decades,
providing a greater number of agents for prevention and management of thromboembolic …

Warfarin has existed for> 7 decades and has been the anticoagulant of choice for many
thromboembolic disorders. The recent introduction of direct‐acting oral anticoagulants …

AIM: The purpose of this article was to systematically review the literature assessing the
efficacy and safety of phase III clinical trials for each direct oral anticoagulant versus vitamin …

Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines
as the first-line option for the treatment of venous thromboembolism and prevention of stroke …

Aims Patient‐reported outcomes (PROs) are a distinctive method of evaluating patient
response to health care or treatment. This systematic review aimed to analyse the impact of …

Oral vitamin K antagonists (VKAs), warfarin, have been in routine clinical use for almost 70
years for various cardiovascular conditions. Direct-Acting Oral Anticoagulants (DOACs) have …

It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …

A major advancement in the field of medicine has been the introduction and usage of direct
oral anticoagulants (DOACs) such as dabigatran (Pradaxa), apixaban (Eliquis), and …